Research programme: BACE1 protein inhibitors - Medivir ABAlternative Names: Alzheimer's disease protease inhibitors - Medivir AB
Latest Information Update: 27 Jun 2008
At a glance
- Originator Medivir AB
- Mechanism of Action BACE1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 27 Jun 2008 Research and compound optimisation is ongoing for Alzheimer's disease in Sweden
- 08 Nov 2004 Early research in Alzheimer's disease in Sweden (unspecified route)